So, it was a healthy start to the year, M&A-wise, for one of the worst-performing sectors of the S&P 500® in 2024. The Health ...

Major deals, including Johnson & Johnson’s $14.6B Intra-Cellular acquisition, signal renewed dealmaking, supported by nearly ...

Chief R&D and commercial officer Najat Khan, PhD, tells GEN Edge the company aims to improve design of studies, accelerate enrollment, and enhance evidence generation.

ASX rises despite Wall Street dip, Alibaba’s AI shakes Nvidia, Lovisa hit with class action and IGO posts quarterly earnings ...

JonesResearch initiated coverage of OnKure Therapeutics (OKUR) with a Buy rating and $32 price target. The clinical stage precision oncology ...

Roche’s freshly approved PI3K inhibitor Itovebi can help extend the lives of certain patients with breast cancer when used in ...

The word on San Francisco’s famously hilly streets is that big pharma is ready to go shopping in 2025, following a flurry of ...

Meanwhile, Eli Lilly announced plans to acquire Scorpion Therapeutics’ STX-478, a P13K inhibitor which is in phase I trials ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

Relay Therapeutics Inc. (NASDAQ:RLAY) is a leading clinical-stage precision medicines firm focused on cancer treatments. The ...

The J&J deal would be the biggest biotech deal in over a year and will add treatments for disorders of the central nervous ...